Literature DB >> 33931816

Left atrial assist device for heart failure with preserved ejection fraction: initial results with torque control mode in diastolic heart failure model.

Chihiro Miyagi1, Barry D Kuban2,3, Christine R Flick1, Anthony R Polakowski1, Takuma Miyamoto1, Jamshid H Karimov1, Randall C Starling4,5, Kiyotaka Fukamachi1.   

Abstract

A novel pump, the left atrial assist device (LAAD), is a device specifically for the treatment of heart failure with preserved ejection fraction (HFpEF). The LAAD is a mixed-flow pump that is implanted in the mitral position and delivers blood from the left atrium to the left ventricle. During the development process, we aimed to explore whether device activation in torque control (TC) mode would improve the function of the LAAD. The TC mode causes adjustment of the pump speed automatically during each cardiac cycle in order to maintain a specified torque. In this study, we tested four different TC settings (TC modes 0.9, 1.0, 1.25, and 1.5) using an in vitro mock circulatory loop. Mild, moderate, and severe diastolic heart failure (DHF) conditions, as well as normal heart condition, were simulated with the four TC modes. Also, we evaluated the LAAD in vivo with three calves. The LAAD was implanted at the mitral position with four TC settings (TC modes 0.9, 1.0, 1.1, 1.2). With LAAD support, the in vitro cardiac output and aortic pressure recovered to normal heart levels at TC 1.25 and 1.5 even under severe DHF conditions with little pump regurgitation. The TC mode tested in vivo with three calves, and it also showed favorable result without elevating the left ventricular end-diastolic pressure. These initial in vitro and in vivo results suggest that the TC mode could be potentially effective, and the LAAD could be a treatment option for HFpEF patients.

Entities:  

Keywords:  Continuous-flow assist device; Device-based therapy; Diastolic dysfunction; Mechanical circulatory support

Year:  2021        PMID: 33931816     DOI: 10.1007/s10741-021-10117-6

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  31 in total

1.  Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.

Authors:  Michael R Zile; John S Gottdiener; Scott J Hetzel; John J McMurray; Michel Komajda; Robert McKelvie; Catalin F Baicu; Barry M Massie; Peter E Carson
Journal:  Circulation       Date:  2011-11-07       Impact factor: 29.690

2.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

3.  Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.

Authors:  Eldrin F Lewis; Gervasio A Lamas; Eileen O'Meara; Christopher B Granger; Mark E Dunlap; Robert S McKelvie; Jeffrey L Probstfield; James B Young; Eric L Michelson; Katarina Halling; Jonas Carlsson; Bertil Olofsson; John J V McMurray; Salim Yusuf; Karl Swedberg; Marc A Pfeffer
Journal:  Eur J Heart Fail       Date:  2006-12-21       Impact factor: 15.534

4.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

5.  Outcome of heart failure with preserved ejection fraction in a population-based study.

Authors:  R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

Review 6.  Heart failure with preserved ejection fraction: from mechanisms to therapies.

Authors:  Carolyn S P Lam; Adriaan A Voors; Rudolf A de Boer; Scott D Solomon; Dirk J van Veldhuisen
Journal:  Eur Heart J       Date:  2018-08-07       Impact factor: 29.983

7.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Authors:  Scott D Solomon; John J V McMurray; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Brian Claggett; Pardeep S Jhund; Sergey A Boytsov; Josep Comin-Colet; John Cleland; Hans-Dirk Düngen; Eva Goncalvesova; Tzvetana Katova; Jose F Kerr Saraiva; Małgorzata Lelonek; Bela Merkely; Michele Senni; Sanjiv J Shah; Jingmin Zhou; Adel R Rizkala; Jianjian Gong; Victor C Shi; Martin P Lefkowitz
Journal:  N Engl J Med       Date:  2019-09-01       Impact factor: 91.245

Review 8.  Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus.

Authors:  Hidekazu Tanaka; Ken-Ichi Hirata
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

9.  Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison.

Authors:  Kwadwo Osei Bonsu; Poukwan Arunmanakul; Nathorn Chaiyakunapruk
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

10.  Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.

Authors:  Hidekazu Tanaka; Fumitaka Soga; Kazuhiro Tatsumi; Yasuhide Mochizuki; Hiroyuki Sano; Hiromi Toki; Kensuke Matsumoto; Junya Shite; Hideyuki Takaoka; Tomofumi Doi; Ken-Ichi Hirata
Journal:  Cardiovasc Diabetol       Date:  2020-01-07       Impact factor: 9.951

View more
  3 in total

1.  A Multi-Domain Simulation Study of a Pulsatile-Flow Pump Device for Heart Failure With Preserved Ejection Fraction.

Authors:  Caglar Ozturk; Luca Rosalia; Ellen T Roche
Journal:  Front Physiol       Date:  2022-01-25       Impact factor: 4.566

2.  In vitro benchtop mock circulatory loop for heart failure with preserved ejection fraction emulation.

Authors:  Andrew Malone; Sean Gallagher; Jemil Saidi; Gina Rizq; Enda O'Dowd; Derek Vallence; Aamir Hameed
Journal:  Front Cardiovasc Med       Date:  2022-07-22

Review 3.  Novel approaches for left atrial pressure relief: Device-based monitoring and management in heart failure.

Authors:  Chihiro Miyagi; Taiyo Kuroda; Jamshid H Karimov; Kiyotaka Fukamachi
Journal:  Front Cardiovasc Med       Date:  2022-08-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.